Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH.

Background and Aim Nonalcoholic fatty liver disease (NAFLD) affects 15–40 % of the general population; 10–20 % of those patients have a more severe form of the disease known as nonalcoholic steatohepatitis (NASH). Cytokeratin-18 (CK18), released during apoptosis and one of the most studied biomarkers in NASH, can be measured by a number of commercially available kits. We compared serum measurements of the CK18 M30 from two different kits using the same cohort to evaluate the reliability between two test kits.